-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharmaceutical (600276.SH) subsidiary obtains drug clinical trial approval notice

Zhitongcaijing·08/04/2026 09:49:02
Listen to the news

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiaries Suzhou Shengdia Biomedical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for injectable SHR-A2009 and adbelimab injections, which will conduct clinical trials in the near future.

According to the “Drug Administration Law of the People's Republic of China” and related regulations, after review, the injectable SHR-A2009 and adbelizumab injections accepted on May 13, 2026 met the relevant requirements for drug registration, and it was agreed that the injectable SHR-A2009 in combination with adaberimab or third-generation EGFRTKI would conduct phase II clinical trials in patients with non-small cell lung cancer.